Benzinga.com

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

The top 10 list reveals bets on electric vehicles, AI, streaming, ecommerce, data analysis, gaming, gene editing, cryptocurrency payments and more. Examining the top 10 list reveals a significant ...
The Lancet

Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial

aDepartment of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Université de Bordeaux Collège Sciences de la Santé, Bordeaux, France bDepartment of Medical Oncology, Institut Curie, St Cloud, ...
ascopubs.org

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Patients with stage III to IV or recurrent, radiographically apparent EC and no previous chemotherapy or disease progression ≥6 months after neo/adjuvant platinum-based chemotherapy were randomly ...
The Lancet

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre ...

aDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, ...
ascopubs.org

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate ...